- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Fabry disease
- Meeting Date: July 2026
Agalsidase alfa, agalsidase beta – July 2026
Solution for I.V. injection 3.5 mg in 3.5 mL vial
Powder for I.V. infusion, 5 mg vial
Powder for I.V. infusion, 35 mg vial
Public Summary Documents
Last updated
13 November 2026
